LLY: ADA Data Reinforces Leadership in Obesity & Diabetes

Research evidence excerpt

LLY: ADA Data Reinforces Leadership in Obesity & Diabetes

Truist Securities

Equity Research Report June 7, 2026

HEALTHCARE: Pharmaceuticals Eli Lilly and Company (LLY)

LLY: ADA Data Reinforces Leadership in Obesity & Diabetes Srikripa Devarakonda, Ph.D.

212-303-4173

Srikripa.Devarakonda@truist.com

Following presentations at ADA, we see Lilly building out a comprehensive portfolio that

could sustain its position as market leader in obesity/T2D. Retatrutide shows best-in-class

Alexander Xenakis weight loss with substantial efficacy at the low 4-mg dose that could lead to widespread 212-590-0954

Alexander.Xenakis@truist.com adoption. Non-incretin Foundayo and eloralintide could fill gaps in current obesity/T2D needs

for patients looking to avoid injections and those more sensitive to GI-related tolerability

issues. With Lilly having mentioned they are still ramping up DTC marketing to consumers, Anna Li we see near-term and longer-term areas for growth that we believe supports LLY share 212-326-6090

Anna.Li@truist.com upside. Reiterate Buy.

Key new nuggets for investors from the presentation.

Stock Rating BUY • One KOL was excited about the eloralintide data believing it could be used as a monotherapy as well as an add-on therapy; also, there is some genetic variance that Unchanged

causes some patients to not respond as well to incretins which could make eloralintide

Price Target $1,281.00 an ideal option for them

Unchanged • KOLs believe that retatrutide could be used more broadly than previously expected given

that the retatrutide low dose (4-mg) data delivered 19% weight loss with a discontinuation

rate less than the pbo arm. This efficacy profile could make it an adequate therapy for

a broad range of patients.

TR to Target 13.7%